PE Fund Investments
Lupin to acquire respiratory therapy brands from US-based Sunovion for $75-M
Publicly-listed, Mumbai-based Lupin Ltd (via its 100% subsidiary Lupin Inc, USA), is to acquire two inhalation-based respiratory therapy brands - Brovana and Xopenex HFA - from the US-based Sunovion Pharmaceuticals Inc, for USD 75 million in cash. The combined annual sales of the two brands being acquired is approximately USD 60 million.
Want to receive such news items in your inbox? Click Here to sign up for a trial.
